<DOC>
	<DOCNO>NCT00811564</DOCNO>
	<brief_summary>A three-month evaluation compare safety efficacy fix combination 0.2 % brimonidine tartrate/0.5 % timolol maleate latanoprost 0.005 % , prostaglandin analogue glaucoma ocular hypertension subject</brief_summary>
	<brief_title>An Evaluation Fixed Combination Brimonidine Tartrate 0.2 % / Timolol Maleate 0.5 % Latanoprost 0.005 % Glaucoma Ocular Hypertension Subjects</brief_title>
	<detailed_description />
	<mesh_term>Hypertension</mesh_term>
	<mesh_term>Glaucoma</mesh_term>
	<mesh_term>Ocular Hypertension</mesh_term>
	<mesh_term>Pharmaceutical Solutions</mesh_term>
	<mesh_term>Latanoprost</mesh_term>
	<mesh_term>Brimonidine Tartrate</mesh_term>
	<mesh_term>Timolol</mesh_term>
	<mesh_term>Maleic acid</mesh_term>
	<mesh_term>Ophthalmic Solutions</mesh_term>
	<criteria>1 . Be least 18 year age ; 2 . Give write informed consent ; 3 . Be good general health determine doctor ; 4 . Have diagnosis unilateral bilateral glaucoma ocular hypertension ; 5 . If female child bear potential , must willing practice effective contraception duration study ( i.e. , abstinence , spermicide , condom , birth control pill ) ; 6 . Understand study instruction , able follow study instruction ; 7 . Be likely complete entire study period ( 12 week ) , include regularly schedule study visit . 1 . Have active ocular disease glaucoma ocular hypertension would interfere study interpretation ; 2 . Any systemic disease clinical evidence condition would make subject , opinion investigator , unsuitable study could potentially confound study result ; 3 . Concurrent participation prior participation investigational drug device study within last 30 day prior Screening Visit</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>August 2011</verification_date>
</DOC>